Objective: The purpose of this study was to evaluate the efficacy and safety of sitagliptin as
an add-on to metformin therapy in patients with moderately severe (hemoglobin A1c≥ 8.0 …

Aims: To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase‐4
inhibitor, for 26 weeks at once‐daily doses of 12.5 and 25 mg in combination with metformin …

There is a rising worldwide prevalence of diabetes, especially type 2 diabetes mellitus (T 2
DM), which is one of the most challenging health problems in the 21st century. The …

Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique
form of disease management for persons with type 2 diabetes mellitus. The aim of this …

Aim: To assess the efficacy and safety of saxagliptin vs. glipizide as add‐on therapy to
metformin in patients with type 2 diabetes mellitus and inadequate glycaemic control on …

Background Although there is general agreement that metformin should be used as first-line
pharmacotherapy in patients with type 2 diabetes, uncertainty remains regarding the choice …

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors represent a new class of oral antihyperglycemic
agents to treat patients with type 2 diabetes. 1 DPP‐4 inhibitors improve fasting and …

Aim: To compare the efficacy and safety of monotherapy with sitagliptin and metformin in
treatment‐naïve patients with type 2 diabetes. Methods: In a double‐blind study, 1050 …

Aim: To assess the addition of sitagliptin to ongoing metformin therapy in patients with type 2
diabetes who were inadequately controlled [haemoglobin A1c (HbA1c) 7–11%] on …

Context: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide are incretins secreted from enteroendocrine cells postprandially in part to …